Investigation Of The Immune Efficiencies Of Bivalent PRV-vector Genetic Engineering Vaccines

Porcine Pseudorabies (PR), foot-and-mouth disease (FMD), porcine reproductive and respiratory syndrome (PRRS) and porcine Japanese encephalitis (JE) are a variety of general infectious diseases in swine industries. They are also important diseases for epidemic prevention on swine groups. Harm caused by these diseases is going beyond great in large scale production.PR, FMD, PRRS, and JE are indispensable for immunoprophylaxis at routine prevention. Good performance on the control of these disease determined for the success of swine production. However, the quality of different vaccines for them exist dissimilarity, and the immune efficiencies are difficult for maintaining shared, specially for the impact form the import vaccines. The quality and efficiencies of vaccines of these diseases bring great stumble for swine production.The genetic engineering vaccines based on PRV developed by Huazhong Agricultural University bring into an important role on the prevention and elimination of PR in our country. In addition, PRV is a perform cartier for developing recombinant vaccines. The bivalent genetic engineering vaccines based on PRV developed by Lab of Animal Infectious Diseases of Huazhong Agricultural University provide a good pathway on solving productive and practical problems. The mature of the technological theory and the effect in-service use provide a new method for the prevention and control of current swine diseases.In the present study, the three developed recombinant PRV vaccines, rPRV-JEV, rPRV-PRRSV, and rPRV-FMDV, were injected the 40-50 days old piglets with PRV, JEV, PRRSV, FMDV negative. The immune efficiencies of the three vaccines were determined by the detection of the antibodies of the immunized piglets.The results obtained confirmed that the immune efficiencies of the bivalent genetic engineering vaccines based on PRV-vector achieve or surpass the same kind of mono-vaccine. The present study provided a selected evidence for the vaccines application in practical production.